Illumina Aims For All-Inclusive Cancer Screen Via New Start-Up
This article was originally published in The Gray Sheet
Genetic sequencing company Illumina is betting it can develop the first next-generation sequencing "pan-cancer" screening assay by building a separate company dedicated to the task. The new firm has $100 million in start-up funds and is called Grail.
Register for our free email digests: